{"id":{"repo_id":"umn","oai_identifier":"oai:conservancy.umn.edu:11299/190602"},"canonical_url":"https://search.dev.ndltd.org/etd/umn/oai:conservancy.umn.edu:11299/190602","repository":{"repo_id":"umn","name":"University of Minnesota","base_url":"https://conservancy.umn.edu/server/oai/request"},"display":{"title":"Efficacy and Feasibility of Fully Automated Closed Loop Insulin Pump Therapy after Islet Auto-Transplantation","abstract":"Background: TPIAT may relieve pain from chronic pancreatitis while minimizing diabetes risk. Avoiding hyperglycemia minimizes islet apoptosis during engraftment. Closed Loop therapy may improve glycemic control in this population. Methods: Analysis of 14 patients (36% male; age 35.9±11.4 years) at transition from IV to subcutaneous insulin (POD=6±1.4 days). Subjects were block randomized to CL pump (n=7) or multiple daily injections (n=7) for 72 hours. Results: Mean glucose was significantly lower in the experimental group than in the control group (111±4 v. 130±13mg/dL; p=0.003). Glycemic variability (StDev 14.1±3.3 v. 21.0±10.2mg/dL; p=0.115), hyperglycemia AUC (2025±1177 v. 7860±11444min*mg/dL; p=0.2045) and hypoglycemia AUC (146±270 v. 1615±4267min*mg/dL; p=0.3813) trended lower in the CL group than in the control group. Discussion: CL therapy was superior to conventional therapy in maintaining euglycemia without increased hypoglycemia. This technology is promising as a tool to maintain euglycemia and minimize hypoglycemia after TPIAT.","abstract_html":"Background: TPIAT may relieve pain from chronic pancreatitis while minimizing diabetes risk. Avoiding hyperglycemia minimizes islet apoptosis during engraftment. Closed Loop therapy may improve glycemic control in this population. Methods: Analysis of 14 patients (36% male; age 35.9±11.4 years) at transition from IV to subcutaneous insulin (POD=6±1.4 days). Subjects were block randomized to CL pump (n=7) or multiple daily injections (n=7) for 72 hours. Results: Mean glucose was significantly lower in the experimental group than in the control group (111±4 v. 130±13mg/dL; p=0.003). Glycemic variability (StDev 14.1±3.3 v. 21.0±10.2mg/dL; p=0.115), hyperglycemia AUC (2025±1177 v. 7860±11444min*mg/dL; p=0.2045) and hypoglycemia AUC (146±270 v. 1615±4267min*mg/dL; p=0.3813) trended lower in the CL group than in the control group. Discussion: CL therapy was superior to conventional therapy in maintaining euglycemia without increased hypoglycemia. This technology is promising as a tool to maintain euglycemia and minimize hypoglycemia after TPIAT.","abstract_has_math":false,"creators":["Forlenza, Gregory"],"institution":null,"degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2015,"date_issued":"2015-05","date_published":"2015-05","updated_at":"2026-07-24T05:19:52Z","subjects":["artificial pancreas","closed loop","continuous glucose monitor","islet auto-transplantation","pancreatitis","total pancreatectomy"],"languages":["en"],"rights":[],"rights_urls":[],"identifier_entries":[]},"links":{"outbound_url":"http://hdl.handle.net/11299/190602","outbound_label":"Handle","outbound_source":"dc:identifier.uri"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:creator","label":"Author","values":["Forlenza, Gregory"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2017-10-09T16:54:56Z"]},{"key":"dc:date.available","label":"Dc Date Available","values":["2017-10-09T16:54:56Z"]},{"key":"dc:date.issued","label":"Date","values":["2015-05"]},{"key":"dc:type","label":"Dc Type","values":["Thesis or Dissertation"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["artificial pancreas","closed loop","continuous glucose monitor","islet auto-transplantation","pancreatitis","total pancreatectomy"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.iso","label":"Language (ISO)","values":["en"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["http://hdl.handle.net/11299/190602"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["University of Minnesota M.S. thesis. May 2015. Major: Clinical Research. Advisor: Antoinette Moran. 1 computer file (PDF); vi, 58 pages."]},{"key":"dc:description.abstract","label":"Abstract","values":["Background: TPIAT may relieve pain from chronic pancreatitis while minimizing diabetes risk. Avoiding hyperglycemia minimizes islet apoptosis during engraftment. Closed Loop therapy may improve glycemic control in this population. Methods: Analysis of 14 patients (36% male; age 35.9±11.4 years) at transition from IV to subcutaneous insulin (POD=6±1.4 days). Subjects were block randomized to CL pump (n=7) or multiple daily injections (n=7) for 72 hours. Results: Mean glucose was significantly lower in the experimental group than in the control group (111±4 v. 130±13mg/dL; p=0.003). Glycemic variability (StDev 14.1±3.3 v. 21.0±10.2mg/dL; p=0.115), hyperglycemia AUC (2025±1177 v. 7860±11444min*mg/dL; p=0.2045) and hypoglycemia AUC (146±270 v. 1615±4267min*mg/dL; p=0.3813) trended lower in the CL group than in the control group. Discussion: CL therapy was superior to conventional therapy in maintaining euglycemia without increased hypoglycemia. This technology is promising as a tool to maintain euglycemia and minimize hypoglycemia after TPIAT."]},{"key":"dc:title","label":"Title","values":["Efficacy and Feasibility of Fully Automated Closed Loop Insulin Pump Therapy after Islet Auto-Transplantation"]}]}],"canonical_facts":{"dc:creator":["Forlenza, Gregory"],"dc:date.accessioned":["2017-10-09T16:54:56Z"],"dc:date.available":["2017-10-09T16:54:56Z"],"dc:date.issued":["2015-05"],"dc:description":["University of Minnesota M.S. thesis. May 2015. Major: Clinical Research. Advisor: Antoinette Moran. 1 computer file (PDF); vi, 58 pages."],"dc:description.abstract":["Background: TPIAT may relieve pain from chronic pancreatitis while minimizing diabetes risk. Avoiding hyperglycemia minimizes islet apoptosis during engraftment. Closed Loop therapy may improve glycemic control in this population. Methods: Analysis of 14 patients (36% male; age 35.9±11.4 years) at transition from IV to subcutaneous insulin (POD=6±1.4 days). Subjects were block randomized to CL pump (n=7) or multiple daily injections (n=7) for 72 hours. Results: Mean glucose was significantly lower in the experimental group than in the control group (111±4 v. 130±13mg/dL; p=0.003). Glycemic variability (StDev 14.1±3.3 v. 21.0±10.2mg/dL; p=0.115), hyperglycemia AUC (2025±1177 v. 7860±11444min*mg/dL; p=0.2045) and hypoglycemia AUC (146±270 v. 1615±4267min*mg/dL; p=0.3813) trended lower in the CL group than in the control group. Discussion: CL therapy was superior to conventional therapy in maintaining euglycemia without increased hypoglycemia. This technology is promising as a tool to maintain euglycemia and minimize hypoglycemia after TPIAT."],"dc:identifier.uri":["http://hdl.handle.net/11299/190602"],"dc:language.iso":["en"],"dc:subject":["artificial pancreas","closed loop","continuous glucose monitor","islet auto-transplantation","pancreatitis","total pancreatectomy"],"dc:title":["Efficacy and Feasibility of Fully Automated Closed Loop Insulin Pump Therapy after Islet Auto-Transplantation"],"dc:type":["Thesis or Dissertation"]},"updated_at":"2026-07-24T05:19:52Z"}